An expert from the University of Texas Southwestern Medical Center in Dallas gives an overview of the multimodal use of stereotactic radiation for the treatment of patients with metastatic kidney cancer.

The first-in-class Heat Shock Factor 1 pathway inhibitor NXP800, the subject of an ongoing phase 1 dose-escalation study, has been granted a Fast Track designation for the treatment of platinum-resistant ovarian cancer by the FDA.

According to a retrospective chart review, there was no significant correlation between BMI and changes in renal function among patients who underwent partial nephrectomy for the treatment of kidney cancer.

At a median follow-up of 17.4 months, half of the enrolled patients with metastatic castration-resistant prostate cancer experienced a decrease in PSA level from baseline following treatment with tazemetostat in combination with abiraterone acetate or enzalutamide.

The findings, according to the lead study author from UC San Diego School of Medicine, are a proof of concept and need to be confirmed in a phase 2 trial.

Findings from an interim analysis of data show that the addition of blue light cystoscopy to conventional white light significantly improved clinical outcomes in a group of patients with non–muscle-invasive bladder cancer.

All patients with chemo-naïve metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy.

Patients with newly diagnosed prostate cancer benefitted from 18F-rHPSMA-7.3 PET when used prior to surgery.

An expert from the University of Texas Southwestern Medical Center in Dallas emphasized that stereotactic radiation provides oncologists with an alternative modality for treating patients with kidney cancer for whom standard ablative surgery.

The FDA’s approval of oral olutasidenib provides adults with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation a new treatment option.